DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 3B — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 3B maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 3b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
plakophilin 2 (PKP2) — PKP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3TT9 · 1.55 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A prospective post-mortem study of 5252 necropsies in Trieste from 1987 to 1989 found an incidence of dilated cardiomyopathy discovered at autopsy of 4.5 per 100,000 per year (24 cases) and a clinical incidence of 2.45 per 100,000 per year (13 cases), giving a total incidence of 6.95 per 100,000 new cases per year. A possible family history was noted in three patients (12.5%), and in 15 patients (62.5%) death was due to cardiological complications. Endocardial thickening, fatty infiltration and arterial involvement were more frequent in patients over 65 years. The authors concluded that the incidence in Europe was higher than previously suggested.
A 1989 review stated that the natural history of dilated cardiomyopathy varies from death within two years in 50 percent of patients to survival beyond ten years in 25 percent, and that at least 11,000 new cases are diagnosed each year in the United States. A 2023 paper on management of non-ischemic dilated cardiomyopathy noted that heart failure remains a leading cause of morbidity and mortality globally, and that only 25 to 40 percent of diagnosed patients receive guideline-directed medical therapy. A 2011 prospective cohort study of 373 patients with recent-onset non-ischemic dilated cardiomyopathy (mean symptom duration 2.2 months, mean age 45, 21% black, 38% women) reported that outcomes improved with contemporary evidence-based therapies including beta-blockers, but the abstract does not provide survival or response rates.
What is still missing is a clear understanding of which patients benefit from specific immunosuppressive or anti-inflammatory regimens, as the 1989 review discussed immunosuppression without reporting controlled trial results. No large randomised trial has established a standard treatment for the subset of patients with inflammatory or autoimmune dilated cardiomyopathy. Funding for such a trial, better patient stratification by biopsy or biomarker, and prospective registries that track long-term outcomes on contemporary therapy are all lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
European Heart Journal · 1997 · 92 citations · open access
Epidemiology of dilated cardiomyopathy: A prospective post-mortem study of 5252 necropsies
AbstractUNLABELLED: Dilated cardiomyopathy is a heart muscle disease of unknown aetiology, characterized by left ventricular dilatation and impaired systolic function. Data on the incidence and prevalence of the disease is ambiguous, due to geographic variations, patient selection and the diagnostic criteria adopted. METHODS: All the post-mortem and clinical cases observed in a consecutive series of 5252 patients resident in Trieste during the period November 1987-November 1989 were studied. RESULTS: Incidence of the disease discovered at autopsy was estimated at 4.5/100,000/year (24 cases), while clinical incidence in the same period was 2.45/100,000/year (13 cases). This is a total incidence of 6.95/100,000 new cases a year. A possible family history of heart muscle disease was found in three patients (12.5%). In 15 patients (62.5%) deaths were due to cardiological complications. Endocardial thickening (P = 0.03), fatty infiltration (P = 0.01) and arterial involvement (P = 0.04) were found more frequently in older patients (> 65 years). CONCLUSIONS: The study confirms that dilated cardiomyopathy in Europe has a higher incidence than previously suggested and emphasizes the need for greater diagnostic sensitivity, particularly since pharmacological treatment is now so effective.
AbstractINTRODUCTION: Phendimetrazine is a medication currently being used to help patients with weight loss. It shares a chemical structure with amphetamines. As such, it shares some of the same toxicities, which can include cardiac toxicity. This case highlights this principle. CASE PRESENTATION: a 54 year old Caucasian female presented to our urgent care facility with complaints of chest pains and other symptoms suggestive of acute coronary syndrome. Ultimately, she was transferred to the emergency room. After evaluation there, it appeared she was having demand ischemia from prescription diet pills CONCLUSION: This case report demonstrates the potential dangers of amphetamine based diet pills. There have been other cases of cardiomyopathies related to phendimetrazine, but it is something that is rarely recognized in an outpatient setting. A case such as this demonstrates the importance of obtaining a careful medication history in all patients and in recognizing diet pills with an amphetamine base can cause cardiac toxicity.
New England Journal of Medicine · 1989 · 10 citations
Immunosuppression for Dilated Cardiomyopathy
AbstractThe diagnosis of dilated cardiomyopathy is made when left ventricular dilatation and systolic dysfunction, with normal wall thickness, occur in the absence of coronary artery, valvular, or pericardial disease.1 The right ventricle is also often involved. The natural history of the disease varies from a course progressing to death within 2 years in 50 percent of afflicted patients2 to survival for more than 10 years in 25 percent. The incidence of dilated cardiomyopathy is increasing; at least 11,000 new cases are diagnosed each year in the United States. The traditional approach to therapy includes cardiac glycosides and diuretics. Although increased . . .
Current Issues in the Diagnosis and Management of Peripartum Cardiomyopathy
AbstractPeripartum cardiomyopathy is a form of heart failure that occurs in women within 1 month pre- and 5 months postdelivery. The syndrome carries a high mortality and predisposing factors are not known. The incidence and prevalence of peripartum cardiomyopathy appear to be increasing and this article aims to alert clinicians to consider a possible diagnosis of peripartum cardiomyopathy, outlines the current treatment options, and describes recent advances in the understanding of the pathophysiology of this condition.
Heart failure journal of India · 2023 · 0 citations · open access
Management of non-ischemic dilated cardiomyopathy
AbstractHeart failure (HF) remains a leading cause of morbidity and mortality globally. For every 23 s, a new case of HF is diagnosed in India. Dilated cardiomyopathy is characterized by dilatation of the left ventricle or both ventricles with impaired function, which cannot be fully explained by abnormal loading conditions or coronary artery disease. The heterogeneity in etiology and clinical presentation of dilated cardiomyopathy makes timely diagnosis and treatment challenging. Even after diagnosis, only 25%–40% receive guideline-directed medical therapy.
Contemporary Treatment Improves Outcomes of Recent-Onset Cardiomyopathy
AbstractStudies of recent-onset dilated cardiomyopathy suggest varied outcomes, but the prognosis with contemporary evidence-based therapies, including beta-blockers, is not known. In this multicenter prospective cohort study, researchers evaluated outcomes among 373 patients (mean age, 45; 21% black; 38% women) with recent-onset, nonischemic, dilated cardiomyopathy (mean symptom duration, 2.2 months) and left ventricular systolic dysfunction of at least moderate severity (mean left …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
